ARK Investment Management LLC has recently announced that it has increased stake in Pacific Biosciences of California Inc (NASDAQ:PACB) by 11.97%. After grabbing 29.82 million shares, the institutional investor is now in possession of 3.19 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.15% having worth around $252.89 million. Moreover, The Vanguard Group, Inc. increased its share by 0.14 million to have a control over 22.69 million shares. And BlackRock Fund Advisors raised its holdings to 0.39 million shares by acquiring 17.58 million shares or 6.57% of the stake.
Pacific Biosciences of California Inc (PACB) concluded trading on 01/03/24 at a closing price of $9.21, with 6.64 million shares of worth about $61.19 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.33% during that period and on Wednesday the price saw a loss of about -3.96%. Currently the company’s common shares owned by public are about 267.44M shares, out of which, 256.40M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 15 analysts are covering the PACB stock and their offered price forecasts bring an average price target of $12.12. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $19.00 and could fall to a lowest price of $8.00. The stock’s current price level is 24.01% above of average price target set by the analysts, while a rise to estimated low would result in loss of -15.13% for the stock. However, touching the estimated high of $19.00 would mean a gain of 51.53% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 22 times over the past 12 months. They bought 1,353,687 shares in 7 of the transactions. In 15 selling transactions, insiders dumped 258,239 shares.
ARK Innovation ETF, ARK Genomic Revolution ETF, and Nikko AM Global Umbrella Fund – A are the top 3 mutual funds which are holding stakes in Pacific Biosciences of California Inc ARK Innovation ETF is currently holding 18.87 million shares of worth totaling $160.04 million. The company recently came selling -0.14 million shares which brought its stake up to 7.06% of the company’s outstanding shares. Nikko AM Global Umbrella Fund – A, after selling 7.51 million shares, have now control over 2.81% of the stake in the company. It holds -0.31 million shares of worth $63.73 million.
Pacific Biosciences of California Inc (NASDAQ: PACB) started trading at $9.31, below -$0.28 from concluding price of the previous day. However, the stock later moved at a day high price of 9.33, or with a loss of -3.96%. Stock saw a price change of -10.41% in past 5 days and over the past one month there was a price change of 3.72%. Year-to-date (YTD), PACB shares are showing a performance of -6.12% which increased to 12.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.74 but also hit the highest price of $14.55 during that period. The average intraday trading volume for Pacific Biosciences of California Inc shares is 5.19 million. The stock is currently trading -1.38% below its 20-day simple moving average (SMA20), while that difference is up 12.16% for SMA50 and it goes to -12.33% lower than SMA200.
ARK Investment Management LLC acquired 29.82 million shares of Pacific Biosciences of California Inc having value of about $252.89 million. Data submitted at the U.S SEC by ARK Investment Management LLC revealed that the firm now holds 3.19 million shares in the company valued at close to $29359822.2, or have control over 11.97% stake in the company. Pacific Biosciences of California Inc (NASDAQ: PACB) currently have 267.44M outstanding shares and institutions hold larger chunk of about 92.72% of that. Holding of mutual funds in the company is about 51.04% while other institutional holders and individual stake holders have control over 6.20% and 41.83% of the stake respectively.
The stock has a current market capitalization of $2.46B and its 3Y-monthly beta is at 1.94. It has posted earnings per share of -$1.28 in the same period. It has Quick Ratio of 4.43 while making debt-to-equity ratio of 1.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PACB, volatility over the week remained 5.22% while standing at 6.56% over the month.
Analysts are in expectations that Pacific Biosciences of California Inc (PACB) stock would likely to be making an EPS of $Pacific Biosciences of Californ in the current quarter, while forecast for next quarter EPS is $9.21 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $PROPANC BIOPHARMA INC which is $Ranpak Holdings Corp at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $PharmaCyte Biotech, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 16.20% while it is estimated to increase by 15.21% in next year. EPS is likely to grow at an annualized rate of -1.00% for next 5-years, compared to annual growth of -9.97% made by the stock over the past 5-years.
Analysts at 15 brokerage firms have issued recommendations for the Pacific Biosciences of California Inc (PACB)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.73. Out of those 15 Wall Street analysts, 9 recommended a “Buy” rating, while 5 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on December 14, 2023 offering an Overweight rating for the stock and assigned a target price of $11 to it.
